Regeneron Pharmaceuticals Gets FDA's Approval For Its EYLEA HD Injection 8 Mg To Treat Macular Edema Following Retinal Vein Occlusion

Author: Benzinga Newsdesk | November 19, 2025 04:11pm

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period. The FDA also approved an every 4-week (monthly) dosing option for some patients who may benefit from resuming this dosing schedule across approved indications: wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and RVO.

Posted In: REGN